CRB
CRSP icon

Chad R. Baker’s CRISPR Therapeutics CRSP Stock Holding History

Chad R. Baker’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-93,300
Closed -$4.44M – 54
2026
Q1 		$4.44M Buy
93,300
+30
+0% +$1.58K 0.84% 32
2025
Q4 		$4.96M Buy
93,270
+65
+0.1% +$3.89K 0.89% 32
2025
Q3 		$6.04M Hold
93,205
– – 1.04% 34
2025
Q2 		$4.53M Hold
93,205
– – 0.84% 36
2025
Q1 		$3.17M Hold
93,205
– – 0.65% 40
2024
Q4 		$3.67M Sell
93,205
-6,075
-6% -$287K 0.72% 40
2024
Q3 		$4.66M Buy
99,280
+760
+0.8% +$38.6K 0.92% 34
2024
Q2 		$5.32M Hold
98,520
– – 1.11% 32
2024
Q1 		$6.72M Hold
98,520
– – 1.43% 29
2023
Q4 		$6.17M Buy
98,520
+46,420
+89% +$2.57M 1.39% 28
2023
Q3 		$2.36M Buy
+52,100
New +$2.69M 0.6% 38

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Chad R. Baker's CRSP Position: Q2 2026 in Review

Chad R. Baker sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 93,300 shares — an estimated $4.44M sold.

Chad R. Baker first reported a position in CRSP in Q3 2023 and held it in 11 quarters. The position peaked at $6.72M in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Chad R. Baker reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Chad R. Baker sold 93,300 CRISPR Therapeutics shares in Q2 2026, an estimated $4.44M.
  • Chad R. Baker first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 11 quarters.
  • Chad R. Baker's CRISPR Therapeutics position peaked at $6.72M in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Chad R. Baker's 13F filing for Q2 2026, filed 16 Jul 2026.